Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H1 2017

  • ID: 4315546
  • Report
  • 36 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Pfizer Inc
  • ProQR Therapeutics NV
  • RaNA Therapeutics Inc
  • Voyager Therapeutics Inc
  • MORE
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H1 2017

Summary:

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Frataxin is a protein encoded by the FXN gene. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe2+ to proteins involved in these pathways. It plays a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe2+ to Fe3.

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Friedreich Ataxia.

The latest report Frataxin Mitochondrial - Pipeline Review, H1 2017, outlays comprehensive information on the Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1)
  • The report reviews Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Pfizer Inc
  • ProQR Therapeutics NV
  • RaNA Therapeutics Inc
  • Voyager Therapeutics Inc
  • MORE
  1. Introduction
  2. Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Overview
  3. Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Companies Involved in Therapeutics Development
  14. Pfizer Inc
  15. ProQR Therapeutics NV
  16. RaNA Therapeutics Inc
  17. Voyager Therapeutics Inc
  18. Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Drug Profiles
  19. AGIL-FA - Drug Profile
  20. Product Description
  21. Mechanism Of Action
  22. R&D Progress
  23. CTI-1601 - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. Gene Therapy to Activate Frataxin for Friedreich’s Ataxia - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. Gene Therapy to Activate Frataxin for Friedreich’s Ataxia - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. JOT-101 - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. Oligonucleotide to Activate Frataxin for Friedreich's Ataxia - Drug Profile
  44. Product Description
  45. Mechanism Of Action
  46. R&D Progress
  47. QRX-604 - Drug Profile
  48. Product Description
  49. Mechanism Of Action
  50. R&D Progress
  51. Small Molecules to Activate Frataxin for Friedreich Ataxia - Drug Profile
  52. Product Description
  53. Mechanism Of Action
  54. R&D Progress
  55. VYFXN-01 - Drug Profile
  56. Product Description
  57. Mechanism Of Action
  58. R&D Progress
  59. Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Dormant Products
  60. Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Product Development Milestones
  61. Featured News & Press Releases
  62. Aug 02, 2016: Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich’s Ataxia
  63. Appendix
  64. Methodology
  65. Coverage
  66. Secondary Research
  67. Primary Research
  68. Expert Panel Validation
  69. Contact Us
  70. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products under Investigation by Universities/Institutes, H1
  7. Products under Investigation by Universities/Institutes, H1
  8. Number of Products by Stage and Mechanism of Actions, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Pipeline by Pfizer Inc, H1
  12. Pipeline by ProQR Therapeutics NV, H1
  13. Pipeline by RaNA Therapeutics Inc, H1
  14. Pipeline by Voyager Therapeutics Inc, H1
  15. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products by Mechanism of Actions, H1
  3. Number of Products by Stage and Mechanism of Actions, H1
  4. Number of Products by Routes of Administration, H1
  5. Number of Products by Stage and Routes of Administration, H1
  6. Number of Products by Molecule Types, H1
  7. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • ProQR Therapeutics NV
  • RaNA Therapeutics Inc
  • Voyager Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll